Tuesday, October 31, 2023 5:47:01 PM
Not bad
Tomorrow is another day, meaning will the price trend north for days that become weeks that become months
Tomorrow is another day, meaning will the price trend north for days that become weeks that become months
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent PSTV News
- Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ • GlobeNewswire Inc. • 04/23/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:04 PM
- Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/22/2026 08:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 12:30:16 PM
- Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/21/2026 11:30:00 AM
- Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 12:01:12 PM
- Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline • GlobeNewswire Inc. • 04/09/2026 11:30:00 AM
- Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment • IH Market News • 04/08/2026 02:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2026 11:30:07 AM
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas • GlobeNewswire Inc. • 04/08/2026 11:30:00 AM
- Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:30:12 PM
- Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives • GlobeNewswire Inc. • 04/02/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:30:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:30:03 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:30:19 PM
- Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/31/2026 08:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:25:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:20:15 PM
- Plus Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 03/31/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:33:06 PM
- Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors • GlobeNewswire Inc. • 03/26/2026 11:30:00 AM
